DYRK1A and non-small cell lung carcinoma: In this context, we first demonstrated that the DYRK1A inhibitor harmine could inhibit the proliferation of NSCLC cells in a dose‐dependent manner compared to that of the controls, indicating that targeting DYRK1A might be effective in treating patients with NSCLC (Figure 1C).